Century Therapeutics Inc (IPSC) - Total Liabilities
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has total liabilities worth $64.77 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Century Therapeutics Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Century Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Century Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Century Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lindex Group
HE:LINDEX
|
Finland | €872.50 Million |
|
PEPPER MONEY LTD.
F:X95
|
Germany | €17.53 Billion |
|
Taiwan Paiho Ltd
TW:9938
|
Taiwan | NT$17.22 Billion |
|
Ocugen Inc
NASDAQ:OCGN
|
USA | $51.10 Million |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
China | CN¥178.36 Million |
|
Samji Electronics Co. Ltd
KQ:037460
|
Korea | ₩1.73 Trillion |
|
Burstone Group Limited
JSE:BTN
|
South Africa | ZAC9.09 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Century Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Century Therapeutics Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Century Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Century Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Century Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.77 Million | -66.24% |
| 2024-12-31 | $191.85 Million | +9.04% |
| 2023-12-31 | $175.94 Million | -4.28% |
| 2022-12-31 | $183.81 Million | +346.81% |
| 2021-12-31 | $41.14 Million | -80.70% |
| 2020-12-31 | $213.19 Million | +16.65% |
| 2019-12-31 | $182.75 Million | -68.25% |
| 2016-12-31 | $575.54 Million | +18.67% |
| 2015-12-31 | $484.99 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more